Apeiron was officially informed today by Vienna’s “Zentrum für Innovation und Technologie” (ZIT) that a grant application submitted in April 2012 for the program “FemPower 2012” received final approval.

13 out of a total of 50 participating companies were selected by the jury. Apeiron was awarded the maximum amount possible. The non-repayable grant has a total volume of up to EUR 510.000,- for further development of Apeiron’s APN201 project.

August 22, 2012
View the Post

Apeiron initiates clinical study to investigate prevention of radiation- induced skin damage in breast cancer patients

APEIRON Biologics AG (Apeiron) today announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients. Press release Presseaussendung

February 27, 2012
View the Post

Evotec and APEIRON Biologics start next project on the Cbl-b target

Evotec AG and Apeiron Biologics AG today announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy. Press release Presseaussendung

October 20, 2011
View the Post